Cardiology

George Karpouzas, MD, discusses the results of a study he presented at EULAR 2023 examining associations between bDMARD use and cardiovascular risk later in life.

Announced in a release by Daiichi Sankyo, Inc. and American Regent, Inc., the therapy is now the first and only intravenous iron replacement therapy indicated for adult patients with heart failure who have iron deficiency.

New data from EULAR 2023 offers a comparison of the levels of vascular inflammation among patients with psoriatic arthritis relative to healthy controls.

The analysis of adults with Type 2 diabetes found 33.4% showed signs of undetected CVD, as indicated by elevated levels of 2 cardiac biomarkers, compared to only 16.1% of those without diabetes.

An analysis of 2 population-based cohorts suggests coronary artery calcium scores added to traditional risk-based models showed better discrimination than polygenic risk scores for CHD risk prediction.

Pooling data from half a dozen major population-based cohort studies, a Johns Hopkins-led team provides new insight into the risk of cognitive decline following myocardial infarction among US adults.

Scott Solomon, MD, of Brigham and Women's Hospital, discusses how baseline patient characteristics inform what cardiologists might learn from the FINEARTS-HF trial, which he presented at Heart Failure 2023.

Differences in Lp(a) level distribution across the diverse US Hispanic or Latino population may have important implications for its use in ASCVD risk assessment.

Ahead of the sotagliflozin approval, Deepak Bhatt, MD, MPH, offers perspective into potential future research opportunities for the SGLT1/2 inhibitor and discusses the impact of a 3rd agent boasting SGLT2 inhibition receiving approval for heart failure.

The FDA approval of sotagliflozin (Inpefa) for the treatment of heart failure was announced by Lexicon Pharmaceuticals on May 26, 2023.

A posthoc analysis of the EMPEROR-Preserved trial suggested empagliflozin decreased the risk of heart failure hospitalization or cardiovascular death, regardless of background diuretic status.

An analysis of the UK Biobank found menstrual cycles less than 21 days or longer than 35 days were associated with a 19% higher risk of CVD compared with a regular menstrual cycle length.

Data from the open-label extension period of the APOLLO-B trial provide new insight into the benefits of patisiran in patients with ATTR amyloidosis with cardiomyopathy.

An analysis of data from the NODE-303 trial provides insight into the effects of etripamil nasal spray in people with atrial fibrillation with rapid ventricular rates.

Muthiah Vaduganathan, MD, MPH, offers perspective on data from the PARAGLIDE-HF trial as well as a pooled analysis of data from the PARAGLIDE-HF and PARAGON-HF trials.

Presented at ESC HFA 2023, results of PARAGLIDE-HF detail the effects of sacubitril/valsartan on NT-proBNP and multiple clinical outcomes, relative to valsartan alone, in patients with HFmrEF or HFpEF.

In this episode of Don’t Miss a Beat, hosts sit down at ESC HFA to discuss key takeaways from the ACC's expert clinical decision pathway and preview HFpEF data scheduled to be presented during the meeting.

An analysis of data from donors within the UNOS network suggests donor hearts from patients who were COVID-19 who were COVID-19 positive could place patients at increased risk of mortality.

Our latest cardiology case report from Brady Pregerson, MD, features a woman in her 60s with a history of sick sinus syndrome presenting with palpitations, SOB, and lightheadedness. Can you determine the correct diagnosis?

An analysis of the National Inpatient Sample offers a deep dive into the risk of adverse outcomes associated with presence of polymyositis or dermatomyositis among patients with congestive heart failure.

Data show older age, being female, having a high BMI, smoking, comorbidities, and previous hospitalization or ICU admission with COVID-19 were associated with an increased risk of developing Post-COVID-19 condition.

Each month, our editorial staff compiles a recap of the top news in cardiology from the past month. Our April 2023 month in review features new data and documents related to heart failure management, recaps and forecasts of top regulatory decisions, and other top news!

Leveraging data from the UK Biobank study, a new study offers insight into the risk of new-onset heart failure based on female reproductive risk factors among a cohort more than 220,000 women.

An analysis of data from more than 119,000 pregnancies suggests women with prenatal depression were at increased risk for multiple forms of cardiovascular disease within the first 2 years following delivery relative to their counterparts without prenatal depression.

A study of more than 3000 Mediterranean adults is shedding light on the impact of longer midday naps on risk of metabolic syndrome, fasting glucose, and diastolic blood pressure.

While age and fat mass were inversely associated with cardiorespiratory fitness (CRF), the physical activity index was positively associated with CRF.

New data from the POISE-3 trial indicates adherence to a preoperative hypotension avoidance strategy was no more effective than a hypertension-avoidance strategy for reducing risk of postoperative adverse events.

An analysis of data from 3 European countries provides insight into the apparent increase in risk of atrial fibrillation associated with preterm births as well as LGA or SGA births.

In patients hospitalized with acute coronary syndrome and metabolic syndrome, obstructive sleep apnea was associated with an increased risk of major adverse cardiovascular and cerebrovascular events in women, but not in men.